Cytokinetics (CYTK) Competitors $56.42 +0.10 (+0.17%) As of 02:14 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CYTK vs. BNTX, TEVA, GMAB, SMMT, RDY, ASND, VTRS, ROIV, QGEN, and BBIOShould you be buying Cytokinetics stock or one of its competitors? The main competitors of Cytokinetics include BioNTech (BNTX), Teva Pharmaceutical Industries (TEVA), Genmab A/S (GMAB), Summit Therapeutics (SMMT), Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), Viatris (VTRS), Roivant Sciences (ROIV), QIAGEN (QGEN), and BridgeBio Pharma (BBIO). These companies are all part of the "pharmaceutical products" industry. Cytokinetics vs. Its Competitors BioNTech Teva Pharmaceutical Industries Genmab A/S Summit Therapeutics Dr. Reddy's Laboratories Ascendis Pharma A/S Viatris Roivant Sciences QIAGEN BridgeBio Pharma Cytokinetics (NASDAQ:CYTK) and BioNTech (NASDAQ:BNTX) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, media sentiment, valuation, profitability and risk. Is CYTK or BNTX more profitable? BioNTech has a net margin of -12.20% compared to Cytokinetics' net margin of -707.17%. Cytokinetics' return on equity of 0.00% beat BioNTech's return on equity.Company Net Margins Return on Equity Return on Assets Cytokinetics-707.17% N/A -45.52% BioNTech -12.20%-1.84%-1.59% Do analysts prefer CYTK or BNTX? Cytokinetics currently has a consensus price target of $75.86, indicating a potential upside of 34.46%. BioNTech has a consensus price target of $134.56, indicating a potential upside of 26.68%. Given Cytokinetics' stronger consensus rating and higher probable upside, analysts plainly believe Cytokinetics is more favorable than BioNTech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cytokinetics 0 Sell rating(s) 3 Hold rating(s) 12 Buy rating(s) 1 Strong Buy rating(s) 2.88BioNTech 0 Sell rating(s) 3 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.79 Which has more risk and volatility, CYTK or BNTX? Cytokinetics has a beta of 0.67, meaning that its share price is 33% less volatile than the S&P 500. Comparatively, BioNTech has a beta of 1.45, meaning that its share price is 45% more volatile than the S&P 500. Does the media favor CYTK or BNTX? In the previous week, Cytokinetics had 36 more articles in the media than BioNTech. MarketBeat recorded 40 mentions for Cytokinetics and 4 mentions for BioNTech. BioNTech's average media sentiment score of 1.24 beat Cytokinetics' score of 0.11 indicating that BioNTech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cytokinetics 4 Very Positive mention(s) 2 Positive mention(s) 28 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral BioNTech 3 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders believe in CYTK or BNTX? 15.5% of BioNTech shares are held by institutional investors. 2.7% of Cytokinetics shares are held by company insiders. Comparatively, 19.2% of BioNTech shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has higher valuation & earnings, CYTK or BNTX? Cytokinetics has higher earnings, but lower revenue than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than Cytokinetics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCytokinetics$18.47M365.51-$589.53M-$5.10-11.06BioNTech$2.98B8.58-$719.92M-$1.60-66.39 SummaryCytokinetics beats BioNTech on 9 of the 17 factors compared between the two stocks. Get Cytokinetics News Delivered to You Automatically Sign up to receive the latest news and ratings for CYTK and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CYTK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CYTK vs. The Competition Export to ExcelMetricCytokineticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.78B$3.32B$6.09B$10.49BDividend YieldN/A2.29%5.68%4.67%P/E Ratio-11.1121.7677.6126.73Price / Sales365.51261.60519.86203.78Price / CashN/A46.3737.8961.20Price / Book-49.069.8912.536.53Net Income-$589.53M-$52.59M$3.30B$277.12M7 Day Performance11.94%4.44%28,071.37%2.26%1 Month Performance12.86%11.66%28,993.01%9.07%1 Year Performance1.27%28.52%35,796.23%31.90% Cytokinetics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CYTKCytokinetics3.992 of 5 stars$56.42+0.2%$75.86+34.5%+7.1%$6.78B$18.47M-11.11250Trending NewsAnalyst ForecastInsider TradeBNTXBioNTech2.7889 of 5 stars$98.72+2.6%$134.56+36.3%-12.2%$23.13B$2.98B0.006,772Positive NewsTEVATeva Pharmaceutical Industries2.7867 of 5 stars$18.87+2.8%$24.71+31.0%+14.8%$21.05B$16.54B7.3436,830Analyst ForecastOptions VolumeGMABGenmab A/S4.0852 of 5 stars$28.60+1.1%$39.25+37.2%+35.6%$18.14B$3.12B16.542,682Trending NewsAnalyst ForecastAnalyst RevisionSMMTSummit Therapeutics3.1002 of 5 stars$19.10+1.1%$31.87+66.8%+6.8%$14.03B$700K0.00110RDYDr. Reddy's Laboratories3.1189 of 5 stars$14.59-1.9%$16.95+16.2%-11.2%$12.42B$3.81B22.1127,811Positive NewsASNDAscendis Pharma A/S3.414 of 5 stars$196.42-0.6%$244.36+24.4%+37.4%$12.18B$393.54M-38.071,017High Trading VolumeVTRSViatris1.4786 of 5 stars$9.79-1.1%$10.40+6.2%-11.9%$11.54B$14.74B4.1132,000ROIVRoivant Sciences3.7482 of 5 stars$14.94-0.7%$19.94+33.5%+41.7%$10.27B$29.05M0.00860QGENQIAGEN4.4887 of 5 stars$45.72-0.5%$49.69+8.7%+7.3%$10.21B$1.98B19.585,765Positive NewsAnalyst ForecastBBIOBridgeBio Pharma4.3689 of 5 stars$51.54-1.6%$63.94+24.1%+112.4%$10.01B$221.90M0.00400 Related Companies and Tools Related Companies BioNTech Alternatives Teva Pharmaceutical Industries Alternatives Genmab A/S Alternatives Summit Therapeutics Alternatives Dr. Reddy's Laboratories Alternatives Ascendis Pharma A/S Alternatives Viatris Alternatives Roivant Sciences Alternatives QIAGEN Alternatives BridgeBio Pharma Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CYTK) was last updated on 10/3/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredU.S. Government Sparking Crypto RallyU.S. Puts GDP on the Blockchain Could this spark the next crypto supercycle? Discover the altcoins poised t...Crypto 101 Media | SponsoredTilson: “I’m watching HOOD”A strange chasm is coming to Wall Street... It's already creating millionaires and billionaires at the fast...Stansberry Research | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredThe Fed Just Got Kneecapped — Here’s What Happens NextDonald Trump has done it again! This time, with the signing of the highly controversial new law S.1582 — he...Banyan Hill Publishing | SponsoredChina’s message to TrumpPorter Stansberry says this bull market is past the “safe zone” and racing toward an event horizon — and in hi...Porter & Company | SponsoredIs Nvidia about to Trigger Another 150X Opportunity?Nvidia gave investors a chance to make more than 150 times their money with its AI chips, known as graphics pr...InvestorPlace | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cytokinetics, Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Cytokinetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CYTK Stock Alerts